European Archives - Page 910 of 1020 - European Medical Journal

Continue
EMJ
5 Feb 2016

Balancing therapeutics and patient access to new cancer drugs

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…
EMJ
4 Feb 2016

Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD…
EMJ
4 Feb 2016

Olaparib: An opportunity for personalised medicine in BRCA-related ovarian cancer

Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia…
EMJ
4 Feb 2016

Optimising sequencing of new treatments for prostate cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD…
EMJ
4 Feb 2016

A new definition of genetic counselling for ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann…
EMJ
4 Feb 2016

KEYNOTE-010: Pembrolizumab, anti-PD-1, for advanced NSCLC with PD-L1 expression

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
EMJ
4 Feb 2016

Improving outcomes from advanced prostate cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD…
EMJ
4 Feb 2016

Cardio-oncology in multiple myeloma

Ola Landgren, MD, PhD from National Cancer Institute, Bethesda, MD talks about cardio-oncology in multiple myeloma (MM). In this new era of more…
EMJ
4 Feb 2016

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…
EMJ
4 Feb 2016

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…